Bold Therapeutics Inc.

Bold Therapeutics was invited to speak at the 2024 'Metals in Medicine' Gordon Research Conferences on June 24, 2024. Mark Bazett, PhD, Sr Director of Preclinical Development at Bold, presented positive Phase 2 data in colorectal, biliary tract, and gastric cancers. https://lnkd.in/evezgj67 Visit Bold's website: https://lnkd.in/eSSaRju8 #GRC #GordonResearchConferences #oncology

Bold Therapeutics is excited to share positive Phase 2 results for BOLD-100 in advanced metastatic biliary tract and gastric cancers. This data was presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting on June 1st. This news follows positive data in the treatment of advanced colorectal cancer presented at the 2024 ASCO Gastrointestinal Cancers Symposium in January. Thank you to everyone that stopped by our posters! #ASCO24 #ASCO2024 #oncology #gastriccancer https://lnkd.in/eqzNaRZz

Bold Therapeutics is excited to share positive Phase 2 results for BOLD-100 in advanced metastatic biliary tract and gastric cancers. This data was presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting on June 1st. This news follows positive data in the treatment of advanced colorectal cancer presented at the 2024 ASCO Gastrointestinal Cancers Symposium in January. Thank you to everyone that stopped by our posters! #ASCO24 #ASCO2024 #oncology #gastriccancer https://lnkd.in/eqzNaRZz

Dr. Do-Youn Oh’s group at Seoul National University College of Medicine will be presenting at the American Association for Cancer Research (AACR) Annual Meeting on the use of Bold Therapeutics' BOLD-100 in combination with ATR inhibitors as anticancer therapies for the treatment of Pancreatic Ductal Adenocarcinoma (PDAC). Stop by Dr. Oh's poster at Session: Cellular Stress Responses, Poster # 12! https://lnkd.in/evEuTtc3 #AACR24 #AACR2024 #oncology

Bold Therapeutics presented robustly positive Phase 2 results for BOLD-100 in combination with FOLFOX in the treatment of advanced metastatic colorectal cancer at ASCO GI 2024. We are thrilled at the prospect of meaningfully improving patient outcomes while maintaining quality of life, not just in colorectal cancer, but potentially in other difficult-to-treat indications as well. The Bold team is off to a strong start in 2024, with more good news coming soon! https://lnkd.in/e3uqiEuW

Bold Therapeutics presented robustly positive Phase 2 results for BOLD-100 in combination with FOLFOX in the treatment of advanced metastatic colorectal cancer at ASCO GI 2024. We are thrilled at the prospect of meaningfully improving patient outcomes while maintaining quality of life, not just in colorectal cancer, but potentially in other difficult-to-treat indications as well. The Bold team is off to a strong start in 2024, with more good news coming soon! https://lnkd.in/e3uqiEuW

Bold Therapeutics is excited to present data in advanced metastatic colorectal cancer at American Society of Clinical Oncology (ASCO) GI 2024. Come by on Saturday, January 20th to see our poster (Abstract # 143). Hope to see you there! #ASCO2024 #GI24 #ASCO24 #oncology #gastriccancer #colorectalcancer

Looking forward to reconnecting with old friends and colleagues, as well as new potential business partners worldwide in San Francisco this week! 2023 was an exciting year at Bold Therapeutics, with positive interim Ph 2 data presentations at AACR (colorectal cancer) and ASCO (biliary tract and gastric cancer). 2024 already looks to be at least as exciting, with complete Ph 2 data presentations expected at ASCO GI later this month and ASCO later this year. We expect to advance into a pivotal Ph 3 study in 3L mCRC in late 2024. We are pleased to have our success recognized by Life Sciences British Columbia as a '2023 Company to Watch'. Oorah! #LSBC #BIOTECanada #colorectalcancer #gastriccancer

Thank you Life Sciences BC and Lumira Ventures for the excellent event. It was exciting to showcase the work we're doing at Bold Therapeutics Inc. and to meet so many other great companies in BC.